FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4200100535> ?p ?o ?g. }

• W4200100535 endingPage "S407" @default.
• W4200100535 startingPage "S407" @default.
• W4200100535 abstract "Abstract Background New vancomycin dosing guidelines recommend using a 24-hour area under the curve (AUC) goal of 400-600mg*h/L rather than a serum trough concentration 10-20 mg/L. This target has the potential to lower troughs and the occurrence of acute kidney injury (AKI). In summer 2020, we were the first to integrate DoseMeRx® Bayesian software into Epic OneChart®, our electronic medical record, to assist with dosing vancomycin. We sought to determine how doses and trough concentrations changed after software implementation. The study also aimed to establish the sample size needed to assess AKI rates. Methods This quasi-experimental study evaluated patients receiving ≥3 vancomycin doses before software integration (Q1 2020) and after (Q4 2020). Fifty patients in whom an adult 1-compartment model could be used and a trough concentration was measured were randomly selected from each period. Patients age ≤18 years, ≥200kg, or with pre-existing renal failure were excluded. AKI was defined using AKIN criteria of an increase in Scr of ≥ 0.3 mg/dL over 48 hours. Student’s t-test was used for continuous variables and Fischer exact test for categorical outcomes. Results In Q1, 299 patients had ≥3 vancomycin doses with 107 reviewed to reach 50 meeting inclusion criteria. In Q4, 346 had ≥3 doses and 94 were reviewed to include 50 patients. The primary reason for exclusion was no trough concentration. Demographics and indications for vancomycin were well matched. Skin/soft tissue infection was the most common indication for vancomycin (n=16, both Q1 and Q4). Sixteen patients were in the ICU with 8 on vasopressors before integration. There were 10 patients in the ICU and 6 on vasopressors after. Results in Table 1 were not significantly different (all p &gt;0.05). AKI occurred in 5 (10%) patients before integration and 3 (6%) after. Based on this, a sample of 1442 patients, or approximately 15 months of vancomycin AUC-based dosing, will need to be analyzed to achieve 80% power to detect a significant difference in AKI. Table 1. Results related to vancomycin dosing before and after software integration Values reported as mean and standard deviation (SD) unless noted Conclusion Vancomycin doses and trough concentrations were similar in the two groups and AKI rates were numerically lower. This serves as an exploratory analysis to inform a larger study on the effects of integrating Bayesian dosing software for vancomycin dosing. Disclosures Bryan Alexander, PharmD, Astellas Pharma (Advisor or Review Panel member) Trevor C. Van Schooneveld, MD, FACP, BioFire (Individual(s) Involved: Self): Consultant, Scientific Research Study Investigator; Insmed (Individual(s) Involved: Self): Scientific Research Study Investigator; Merck (Individual(s) Involved: Self): Scientific Research Study Investigator; Rebiotix (Individual(s) Involved: Self): Scientific Research Study Investigator Scott J. Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP, Merck & Co., Inc (Grant/Research Support) Scott J. Bergman, PharmD, FCCP, FIDSA, BCPS, BCIDP, Merck & Co., Inc (Individual(s) Involved: Self): Research Grant or Support" @default.
• W4200100535 created "2021-12-31" @default.
• W4200100535 creator A5005331990 @default.
• W4200100535 creator A5007300430 @default.
• W4200100535 creator A5019631032 @default.
• W4200100535 creator A5043677893 @default.
• W4200100535 creator A5053790492 @default.
• W4200100535 date "2021-11-01" @default.
• W4200100535 modified "2023-09-30" @default.
• W4200100535 title "609. Implementation of Bayesian Software for Vancomycin Dosing Integrated into an Electronic Medical Record" @default.
• W4200100535 doi "https://doi.org/10.1093/ofid/ofab466.807" @default.
• W4200100535 hasPublicationYear "2021" @default.
• W4200100535 type Work @default.
• W4200100535 citedByCount "0" @default.
• W4200100535 crossrefType "journal-article" @default.
• W4200100535 hasAuthorship W4200100535A5005331990 @default.
• W4200100535 hasAuthorship W4200100535A5007300430 @default.
• W4200100535 hasAuthorship W4200100535A5019631032 @default.
• W4200100535 hasAuthorship W4200100535A5043677893 @default.
• W4200100535 hasAuthorship W4200100535A5053790492 @default.
• W4200100535 hasBestOaLocation W42001005351 @default.
• W4200100535 hasConcept C126322002 @default.
• W4200100535 hasConcept C144024400 @default.
• W4200100535 hasConcept C149923435 @default.
• W4200100535 hasConcept C194828623 @default.
• W4200100535 hasConcept C2777288759 @default.
• W4200100535 hasConcept C2778980435 @default.
• W4200100535 hasConcept C2779489039 @default.
• W4200100535 hasConcept C2780084366 @default.
• W4200100535 hasConcept C2780472472 @default.
• W4200100535 hasConcept C2909675724 @default.
• W4200100535 hasConcept C2910800852 @default.
• W4200100535 hasConcept C2911091166 @default.
• W4200100535 hasConcept C3018060332 @default.
• W4200100535 hasConcept C31785415 @default.
• W4200100535 hasConcept C523546767 @default.
• W4200100535 hasConcept C54355233 @default.
• W4200100535 hasConcept C71924100 @default.
• W4200100535 hasConcept C86803240 @default.
• W4200100535 hasConceptScore W4200100535C126322002 @default.
• W4200100535 hasConceptScore W4200100535C144024400 @default.
• W4200100535 hasConceptScore W4200100535C149923435 @default.
• W4200100535 hasConceptScore W4200100535C194828623 @default.
• W4200100535 hasConceptScore W4200100535C2777288759 @default.
• W4200100535 hasConceptScore W4200100535C2778980435 @default.
• W4200100535 hasConceptScore W4200100535C2779489039 @default.
• W4200100535 hasConceptScore W4200100535C2780084366 @default.
• W4200100535 hasConceptScore W4200100535C2780472472 @default.
• W4200100535 hasConceptScore W4200100535C2909675724 @default.
• W4200100535 hasConceptScore W4200100535C2910800852 @default.
• W4200100535 hasConceptScore W4200100535C2911091166 @default.
• W4200100535 hasConceptScore W4200100535C3018060332 @default.
• W4200100535 hasConceptScore W4200100535C31785415 @default.
• W4200100535 hasConceptScore W4200100535C523546767 @default.
• W4200100535 hasConceptScore W4200100535C54355233 @default.
• W4200100535 hasConceptScore W4200100535C71924100 @default.
• W4200100535 hasConceptScore W4200100535C86803240 @default.
• W4200100535 hasIssue "Supplement_1" @default.
• W4200100535 hasLocation W42001005351 @default.
• W4200100535 hasLocation W42001005352 @default.
• W4200100535 hasOpenAccess W4200100535 @default.
• W4200100535 hasPrimaryLocation W42001005351 @default.
• W4200100535 hasRelatedWork W1831522254 @default.
• W4200100535 hasRelatedWork W1989051318 @default.
• W4200100535 hasRelatedWork W2154361835 @default.
• W4200100535 hasRelatedWork W2160515228 @default.
• W4200100535 hasRelatedWork W2170749810 @default.
• W4200100535 hasRelatedWork W2899408284 @default.
• W4200100535 hasRelatedWork W2912845088 @default.
• W4200100535 hasRelatedWork W4200100535 @default.
• W4200100535 hasRelatedWork W4225930705 @default.
• W4200100535 hasRelatedWork W2557200397 @default.
• W4200100535 hasVolume "8" @default.
• W4200100535 isParatext "false" @default.
• W4200100535 isRetracted "false" @default.
• W4200100535 workType "article" @default.